GB0416062D0 - Improved N4 chelator conjugates - Google Patents

Improved N4 chelator conjugates

Info

Publication number
GB0416062D0
GB0416062D0 GBGB0416062.8A GB0416062A GB0416062D0 GB 0416062 D0 GB0416062 D0 GB 0416062D0 GB 0416062 A GB0416062 A GB 0416062A GB 0416062 D0 GB0416062 D0 GB 0416062D0
Authority
GB
United Kingdom
Prior art keywords
improved
chelator conjugates
chelator
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0416062.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Amersham PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham PLC filed Critical Amersham PLC
Priority to GBGB0416062.8A priority Critical patent/GB0416062D0/en
Publication of GB0416062D0 publication Critical patent/GB0416062D0/en
Priority to US10/559,886 priority patent/US7785566B2/en
Priority to PCT/NO2004/000335 priority patent/WO2005044313A2/en
Priority to EP04800183A priority patent/EP1699495A2/en
Priority to JP2006537917A priority patent/JP2007510643A/ja
Priority to US10/559,880 priority patent/US7431914B2/en
Priority to EP04808852A priority patent/EP1699494A2/en
Priority to PCT/NO2004/000358 priority patent/WO2005049095A2/en
Priority to JP2006541065A priority patent/JP2007512321A/ja
Priority to RU2007101515/04A priority patent/RU2360701C2/ru
Priority to KR1020077001298A priority patent/KR20070034064A/ko
Priority to JP2007522011A priority patent/JP5557425B2/ja
Priority to BRPI0513456-0A priority patent/BRPI0513456A/pt
Priority to EP05763654.0A priority patent/EP1768708B1/en
Priority to AU2005263942A priority patent/AU2005263942B2/en
Priority to CN2005800297360A priority patent/CN101128219B/zh
Priority to ES05763654.0T priority patent/ES2628935T3/es
Priority to US11/572,161 priority patent/US7767796B2/en
Priority to PCT/GB2005/002807 priority patent/WO2006008496A2/en
Priority to MX2007000744A priority patent/MX2007000744A/es
Priority to CA2573384A priority patent/CA2573384C/en
Priority to KR1020137002190A priority patent/KR20130024963A/ko
Priority to NO20070348A priority patent/NO20070348L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0416062.8A 2003-11-06 2004-07-19 Improved N4 chelator conjugates Ceased GB0416062D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB0416062.8A GB0416062D0 (en) 2004-07-19 2004-07-19 Improved N4 chelator conjugates
US10/559,886 US7785566B2 (en) 2003-11-06 2004-11-05 Pharmaceutical compounds
PCT/NO2004/000335 WO2005044313A2 (en) 2003-11-06 2004-11-05 Conjugates of angiotensin ii and an imaging moiety
EP04800183A EP1699495A2 (en) 2003-11-06 2004-11-05 Conjugates of angiotensin ii and an imaging moiety
JP2006537917A JP2007510643A (ja) 2003-11-06 2004-11-05 医薬化合物
US10/559,880 US7431914B2 (en) 2003-11-24 2004-11-23 Contrast agent
EP04808852A EP1699494A2 (en) 2003-11-24 2004-11-23 Contrast agent imaging angiotensin ii receptors
PCT/NO2004/000358 WO2005049095A2 (en) 2003-11-24 2004-11-23 Contrast agent imaging angiotensin ii receptors
JP2006541065A JP2007512321A (ja) 2003-11-24 2004-11-23 造影剤
KR1020137002190A KR20130024963A (ko) 2004-07-19 2005-07-19 개선된 ｎ4 킬레이트제 결합체
ES05763654.0T ES2628935T3 (es) 2004-07-19 2005-07-19 N4 quelantes conjugados
RU2007101515/04A RU2360701C2 (ru) 2004-07-19 2005-07-19 Усовершенствованные конъюгаты n4 хелатообразующих агентов
JP2007522011A JP5557425B2 (ja) 2004-07-19 2005-07-19 改良ｎ４キレーターコンジュゲート
BRPI0513456-0A BRPI0513456A (pt) 2004-07-19 2005-07-19 complexo de tecnécio, conjugado quelador, radiofármaco, kit para a preparação do radiofármaco, e, composto
EP05763654.0A EP1768708B1 (en) 2004-07-19 2005-07-19 N4 chelator conjugates
AU2005263942A AU2005263942B2 (en) 2004-07-19 2005-07-19 Improved N4 chelator conjugates
CN2005800297360A CN101128219B (zh) 2004-07-19 2005-07-19 改进的n4螯合剂缀合物
KR1020077001298A KR20070034064A (ko) 2004-07-19 2005-07-19 개선된 ｎ4 킬레이트제 결합체
US11/572,161 US7767796B2 (en) 2004-07-19 2005-07-19 N4 chelator conjugates
PCT/GB2005/002807 WO2006008496A2 (en) 2004-07-19 2005-07-19 Improved n4 chelator conjugates
MX2007000744A MX2007000744A (es) 2004-07-19 2005-07-19 Conjugados quelantes de n4 mejorados.
CA2573384A CA2573384C (en) 2004-07-19 2005-07-19 Improved n4 chelator conjugates
NO20070348A NO20070348L (no) 2004-07-19 2007-01-18 Improved N4 Chelator Conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0416062.8A GB0416062D0 (en) 2004-07-19 2004-07-19 Improved N4 chelator conjugates

Publications (1)

Publication Number Publication Date
GB0416062D0 true GB0416062D0 (en) 2004-08-18

Family

ID=32893775

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0416062.8A Ceased GB0416062D0 (en) 2003-11-06 2004-07-19 Improved N4 chelator conjugates

Country Status (14)

Country Link
US (1) US7767796B2 (enExample)
EP (1) EP1768708B1 (enExample)
JP (1) JP5557425B2 (enExample)
KR (2) KR20070034064A (enExample)
CN (1) CN101128219B (enExample)
AU (1) AU2005263942B2 (enExample)
BR (1) BRPI0513456A (enExample)
CA (1) CA2573384C (enExample)
ES (1) ES2628935T3 (enExample)
GB (1) GB0416062D0 (enExample)
MX (1) MX2007000744A (enExample)
NO (1) NO20070348L (enExample)
RU (1) RU2360701C2 (enExample)
WO (1) WO2006008496A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101732736B (zh) * 2009-12-02 2012-04-04 北京师范大学 制备锝-99m标记的DTPA-LSA的药盒及制备方法和应用
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
GB201016206D0 (en) * 2010-09-27 2010-11-10 Ge Healthcare Ltd Apoptosis imaging agents
RU2465011C1 (ru) * 2011-04-27 2012-10-27 Общество с ограниченной ответственностью "ИНТЕРА-МЕД" Радиофармацевтический препарат для диагностики меланомы и ее метастазов
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
RU2655392C1 (ru) * 2017-03-02 2018-05-28 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ получения комплекса технеция-99м с октреотидом для диагностики нейроэндокринных опухолей
CN112105393A (zh) 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
US20250215027A1 (en) * 2021-08-11 2025-07-03 Cancer Research Technology Limited Diphosphine compounds and complexes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
ATE66469T1 (de) * 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
JPH02504387A (ja) * 1987-04-02 1990-12-13 セントカー・カーデイオバスキユラー・イメージング・パートナーズ・エルピー 金属イオンで抗体を標識付けする方法
US4952393A (en) * 1987-04-02 1990-08-28 The General Hospital Corporation Organ infarct imaging with technetium labelled glucarate
US5489425A (en) * 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
NO940080L (no) * 1993-01-12 1994-07-13 Sandoz Ag Polypeptider , fremgangsmåte for deres fremstilling og farmasöytiske preparater derav
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
CA2232411A1 (en) * 1995-09-18 1997-03-27 Mallinckrodt Medical, Inc. (radio) labelled biotin derivatives
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
US7785566B2 (en) * 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
CN1925876A (zh) * 2004-03-04 2007-03-07 通用电气医疗集团股份有限公司 用于诊断和治疗的血管紧张素肽类似物和螯合剂的缀合物

Also Published As

Publication number Publication date
AU2005263942B2 (en) 2009-02-26
EP1768708A2 (en) 2007-04-04
MX2007000744A (es) 2007-06-25
CN101128219B (zh) 2012-06-20
CN101128219A (zh) 2008-02-20
CA2573384C (en) 2013-09-10
US7767796B2 (en) 2010-08-03
US20080131368A1 (en) 2008-06-05
KR20070034064A (ko) 2007-03-27
EP1768708B1 (en) 2017-05-17
CA2573384A1 (en) 2006-01-26
NO20070348L (no) 2007-02-16
KR20130024963A (ko) 2013-03-08
AU2005263942A1 (en) 2006-01-26
WO2006008496A3 (en) 2006-07-27
BRPI0513456A (pt) 2008-05-06
ES2628935T3 (es) 2017-08-04
JP2008510683A (ja) 2008-04-10
JP5557425B2 (ja) 2014-07-23
RU2360701C2 (ru) 2009-07-10
WO2006008496A2 (en) 2006-01-26
RU2007101515A (ru) 2008-08-27

Similar Documents

Publication Publication Date Title
IL186521A0 (en) Nanoparticle-active ingredient conjugates
PL1912671T3 (pl) Koniugaty beta-glukuronid-linker-lek
IL180762A (en) Oligomer-insulin conjugates, formulations containing them and their use
GB2424581B (en) Formulations
PL1877073T3 (pl) Niecytotoksyczne koniugaty białkowe
EP1608735A4 (en) RNAI CONJUGATES
IL191850A0 (en) Targeting vector-phospholipid conjugates
IL185773A0 (en) Formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
IL176918A0 (en) Ghrelin-carrier conjugates
GB0519871D0 (en) Immunogenic agents
GB0402738D0 (en) Sullman offset dental luxator
GB0400128D0 (en) An improved two-phase flow-turbine
IL179208A0 (en) Intereferon formulations
GB0411526D0 (en) Conjugate
GB0400263D0 (en) Micromotor
AU3617P (en) BRA01 Cordyline fruticosa
GB0417248D0 (en) Formulations
GB0417226D0 (en) Formulations
GB0500495D0 (en) Micromotor
GB0401030D0 (en) Mini-chromosomes
SI1966388T1 (sl) Konjugati iz ciljnega vektorja in fosfolipidov
GB0417533D0 (en) Improved SMPSOGI
GB0426293D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)